# Cleerly

> Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.

- **Founded:** 2017
- **Headquarters:** Denver, Colorado, United States
- **Founders:** James K. Min (Founder & CEO (cardiologist))
- **Team size:** ~260 employees
- **Products:** Cleerly LABS, Cleerly ISCHEMIA, Cleerly COMPARE
- **Notable:** FDA 510(k) clearance for Cleerly ISCHEMIA in January 2024 - a first-of-its-kind AI ischemia estimate from CCTA, Secured a Category I CPT code and Medicare coverage for its analyses, Won commercial payer coverage from Aetna

## Products & services

- **Cleerly LABS** — Core AI plaque-analysis platform that ingests coronary CT angiography (CCTA) images, builds a 3D model of the coronary arteries, identifies lumen and vessel walls, locates stenoses, and quantifies and categorizes plaque volume, composition, length and location.
- **Cleerly ISCHEMIA** — FDA-cleared machine-learning decision-support tool that estimates the likely presence or absence of coronary vessel ischemia at a per-vessel level using 37 measures of atherosclerosis, stenosis and vascular morphology from CCTA - a non-invasive alternative signal to invasive FFR.
- **Cleerly COMPARE** — Comparative analysis tool that tracks coronary artery disease progression or regression across serial scans over time.

## Achievements

- FDA 510(k) clearance for Cleerly ISCHEMIA in January 2024 - a first-of-its-kind AI ischemia estimate from CCTA
- Secured a Category I CPT code and Medicare coverage for its analyses
- Won commercial payer coverage from Aetna
- Raised more than $500 million across multiple rounds from top-tier investors
- Built and validated its AI on millions of medical images from tens of thousands of patients across landmark trials

## Latest updates

- **2024-12** — Closed a $106M Series C extension led by Insight Partners, with Battery Ventures joining, to scale commercial growth and clinical evidence generation.
- **2024-01** — Received FDA 510(k) clearance for Cleerly ISCHEMIA, using 37 measures of heart health to estimate per-vessel coronary ischemia.
- **2022-07** — Closed an oversubscribed $223M Series C led by T. Rowe Price and Fidelity.

## Links

- Website: https://cleerlyhealth.com
- LinkedIn: https://www.linkedin.com/company/cleerlyhealth
- Twitter/X: https://twitter.com/cleerly_inc
- Facebook: https://facebook.com/cleerlyhealth

---

Profile page: https://yespress.io/cleerly
Published by YesPress — https://yespress.io
Last updated: 2026-07-21